electroCore, Inc. , a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medical Baltic UAB (“PMB”), whereby PMB will serve as the exclusive distributor of gammaCore Sapphire™ non-invasive vagus nerve stimulation (“nVNS”) to patients suffering from primary headache disorders in Lithuania, Latvia, Belarus, Kazakhstan and Ukraine.
“We are delighted to partner with Pro Medical Baltic to be able to introduce our nVNS therapy to new patients in Eastern Europe,” said Iain Strickland, electroCore’s Vice President of European Operations. “Pro Medical Baltic already has experience working with neuromodulation products, and we look forward to supporting their market access activities for gammaCore. This agreement is hopefully the first of many that will see electroCore, Inc. expand into new markets.”
Pro Medical Baltic has been operating in these countries for five years and has an established network of leading physicians familiar with the benefits of neuromodulation. PMB currently distributes neuromodulation devices such as implantable vagus nerve stimulators and will focus on distributing gammaCore for treatment of cluster headache and refractory migraine. The initial term of the agreement is three years, and the agreement contains customary terms and conditions, such as minimum purchase commitments.
About Pro Medical Baltic
Pro Medical Baltic is a wholesale medical supplier of a wide range of medical devices and medical equipment for hospitals and healthcare centers. Pro Medical Baltic is committed to introducing and promoting the newest methods of treatment for neurological conditions using neuromodulation devices.
For more information, visit http://www.pmbaltic.eu/
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.
For more information, visit www.electrocore.com.
About gammaCore™
gammaCore™ (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients.
gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.
In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.
Investors:
Hans Vitzthum
LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com
or
Media Contact:
Jackie Dorsky
electroCore
973-290-0097
jackie.dorsky@electrocore.com